Highlights from our first expression of interest review round
In November 2024, we closed applications for our inaugural review round. The response was remarkable, with our triage and diligence team receiving a significant number of applications, reflecting the potential of the collaborative approach to drive progress for young patients.
Below, we share some key highlights from this first round.
Our first round in numbers
We received a remarkable response, with applications from both industry and academia.
9
modalities
Over
10
indications
Applications from
12
countries
The quality, quantity, and diversity of applications—spanning stages, modalities, and indications—aligns with our hopes for C-Further. This also underscores the importance of a collaborative approach in accelerating the discovery and delivery of transformative treatments for children and young people.
Sheena Patel
Principal Scientist at Cancer Research Horizons, Triage & diligence workstream